IO

IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

Retrieved on: 
Friday, April 5, 2024
External, Medical biology, IO, Employment, Survival, Pfizer, Business development, Cancer, Engineering, Doctor of Philosophy, Eli Lilly and Company, Kadmon Corporation, Vaccine, Lead, Pharmaceutical industry

NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Faiçal Miyara, Ph.D., has been appointed as the company’s chief business officer.

Key Points: 
  • NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Faiçal Miyara, Ph.D., has been appointed as the company’s chief business officer.
  • Dr. Miyara, who has more than 17 years of experience in the pharmaceutical industry, will be responsible for global business development activities including strategic partnerships.
  • Dr. Miyara will be based in the United States, report to IO Biotech’s CEO, Mai-Britt Zocca, Ph.D., and be a member of the company’s executive team, effective immediately.
  • “We are very excited to welcome Faiçal to IO Biotech,” said Dr. Zocca.

POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks

Retrieved on: 
Wednesday, March 27, 2024
IO, DSP, SAN, LPO, TMX Group, AI, Die (integrated circuit), POET, Programmable interrupt controller, Product management, PTK, Video game

POET and MultiLane will focus on jointly developing pluggable transceivers that will reduce cost and improve power efficiency over existing solutions, and address the increasing need for more scalable hardware components for AI and cloud data center markets.

Key Points: 
  • POET and MultiLane will focus on jointly developing pluggable transceivers that will reduce cost and improve power efficiency over existing solutions, and address the increasing need for more scalable hardware components for AI and cloud data center markets.
  • “Our intent with this collaboration is to design cost-optimized 800G modules that offer superior performance with both the DSP integrated version as well as Linear Pluggable Optics (LPO) variants.
  • We also want to kick start our designs for 1.6T and 3.2T pluggable transceivers for the most advanced data center and AI network operators,” said Raju Kankipati, POET’s SVP of Product Management.
  • “We have to plan and develop ahead of market demand and be ready when customers are ready to test these higher speeds.

BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer

Retrieved on: 
Monday, March 25, 2024
IIT, Radiation, IO, Carcinoma, Survival, NSCLC, Entrepreneurship, Monroe Dunaway Anderson, Patient, Journal, Merck, Overalls, MD, Lung, Neoplasm, Safety, EP, SITC, PFS, PD-L1, Platinum, Horn, Immunotherapy, PD-1, Medical imaging

This Phase 2 trial will evaluate the efficacy and safety of Pembrolizumab, Plinabulin plus EP in 1L ES-SCLC.

Key Points: 
  • This Phase 2 trial will evaluate the efficacy and safety of Pembrolizumab, Plinabulin plus EP in 1L ES-SCLC.
  • KEYNOTE-604 study revealed that 12-month PFS rate in patients with pembrolizumab plus EP is 13.6% vs. 3.1% with placebo plus EP.
  • Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell Lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
  • An Open-Label, Single-Arm, Phase II Study of Pembrolizumab, Plinabulin Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer.

Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA

Retrieved on: 
Wednesday, March 13, 2024
Research, Takeda Pharmaceutical Company, IO, Biotechnology, PFM, University, Patient, Columbia University, Cowen Inc., Doctor of Philosophy, Biochemistry, New Enterprise Associates, CFA, Cancer, Texas A&M University, Pfizer, Chemical engineering, Drug development, NEA, Therapy, ADC, Pharmaceutical industry

BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directors, effective March 12, 2024.

Key Points: 
  • BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directors, effective March 12, 2024.
  • “We are thrilled to have Santhosh join the Pyxis Oncology board.
  • Santhosh brings a wealth of business, investment, strategic, and board experience to our team,” said Lara S. Sullivan, M.D., President and Chief Executive Officer of Pyxis Oncology.
  • "I am delighted to join the Board of Directors at Pyxis Oncology at such a pivotal moment in the Company's journey as they anticipate data readouts for their lead ADC program, PYX-201, and their IO program, PYX-106, in 2024," said Dr. Santhosh Palani.

Avicena Announces Scalable Sub-pJ/bit LightBundle™ Chiplet Interconnect with 10m Reach

Retrieved on: 
Monday, March 25, 2024
Semiconductor, Technology, Mobile, Wireless, Software, 5G, Artificial Intelligence, BOW, HBM, ICS, IO, GPU, Memory, HPC, AI, High Bandwidth Memory, Rump, Graphics processing unit, Scalability, Booth, ChatGPT, Artificial intelligence, Multimedia, MicroLED, UCIe, Video game

Avicena, headquartered in Sunnyvale, CA, is announcing its new scalable LightBundle chiplet interconnect at OFC 2024 in San Diego, CA ( https://www.ofcconference.org/en-us/home/ ).

Key Points: 
  • Avicena, headquartered in Sunnyvale, CA, is announcing its new scalable LightBundle chiplet interconnect at OFC 2024 in San Diego, CA ( https://www.ofcconference.org/en-us/home/ ).
  • The chiplet interconnect extends ultra-high density die-to-die (D2D) connections up to 10m at multi-Tbps/mm shoreline bandwidth density and class leading sub-pJ/bit energy efficiency.
  • The LightBundle chiplet interconnect extends HBM and other ultra-high performance D2D connections up to 10m while dissipating
  • “At Avicena, we are excited to announce our ultra-low power scalable chiplet interconnect based on our LightBundle platform,” says Bardia Pezeshki, Founder and CEO of Avicena.

ASE’s VIPack™ Enables Innovational AI Devices Through Advanced Interconnect Technology for Chiplets

Retrieved on: 
Wednesday, March 20, 2024
Semiconductor, Engineering, Technology, Manufacturing, Artificial Intelligence, Hardware, IO, AP, SOC, Integration, Artificial intelligence, TAIEX, IDE, AI, Senior, Marketing, IP, Creativity, Chiplet, Corporation, Printed circuit board

This interconnect extension advances roadmap capabilities from a chip-on-wafer interconnect pitch of 40um to 20um through advanced microbump technology.

Key Points: 
  • This interconnect extension advances roadmap capabilities from a chip-on-wafer interconnect pitch of 40um to 20um through advanced microbump technology.
  • As the chiplet design approach accelerates, ASE’s advanced interconnect technology allows designers to consider innovative, high density chiplet integration options where there might normally be chip IO density limitations for true 3D layered IP block considerations.
  • ASE’s microbump technology allows for a reduction in pitch from 40um down to 20um using a new metallurgical stack.
  • Fine pitch interconnect capabilities enable a 3D integration capability as well as a higher density for high IO memory considerations.

Agendia Announces New Data from I-SPY 2 Showcasing Ability of New Signature ImPrintTN to Predict Immunotherapy Response in Patients with Triple Negative Breast Cancer

Retrieved on: 
Wednesday, March 20, 2024
Biotechnology, FDA, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Genetics, Science, Clinical Trials, IO, Conference, Entrepreneurship, Response, Immunotherapy, Partnership, Risk, Patient, MammaPrint, University, Biology, University of California, Imprint, Genomics, Breast cancer, Medical laboratory, RPS, Pharmaceutical industry

Agendia®, Inc. today announced new data from the I-SPY 2 trial showcasing its ImPrint signature for patients with triple negative (TN) breast cancer, shared by I-SPY 2 researchers in an oral presentation at the 14th European Breast Cancer Conference in Milan, Italy.

Key Points: 
  • Agendia®, Inc. today announced new data from the I-SPY 2 trial showcasing its ImPrint signature for patients with triple negative (TN) breast cancer, shared by I-SPY 2 researchers in an oral presentation at the 14th European Breast Cancer Conference in Milan, Italy.
  • Agendia has been in partnership with Quantum Leap Healthcare Collaborative, the sponsors of the neoadjuvant biomarker-rich I-SPY 2 trial, since 2010.
  • ), investigates the utility of a refined version of ImPrint, called ImPrintTN, designed to provide more accurate predictions to response to common immunotherapy (IO) regimens for TN patients.
  • “Many immunotherapy treatments can have difficult, severe adverse side effects on patients that can outweigh the benefit of the treatment.

Kibo and OLR Forge Strategic Partnership to Propel Retail Innovation and ROI with Advanced Composable Commerce

Retrieved on: 
Tuesday, March 26, 2024
API, Partnership, Implementation, IO, Commerce, OLR, Kibo, Online shopping

AUSTIN, Texas, March 26, 2024 /PRNewswire-PRWeb/ -- Kibo Commerce, a market leader in composable unified commerce solutions, has announced a strategic partnership with OLR, specialist systems integrator of Oracle Retail Solutions. The collaboration introduces the "Souk Store," an accelerator developed by OLR that expedites the migration of catalogues, content, customers, and site history. This accelerator is built on proven structures that drive conversion, offering an easy-to-navigate experience for users, comprehensive search engine optimization, and offers a seamless transition to Kibo's platform.

Key Points: 
  • Kibo Commerce partners with OLR to introduce the "Souk Store" accelerator, which streamlines migration processes and delivers a modern, seamless retail experience.
  • AUSTIN, Texas, March 26, 2024 /PRNewswire-PRWeb/ -- Kibo Commerce , a market leader in composable unified commerce solutions, has announced a strategic partnership with OLR , specialist systems integrator of Oracle Retail Solutions.
  • The collaboration introduces the "Souk Store," an accelerator developed by OLR that expedites the migration of catalogues, content, customers, and site history.
  • For more information about the partnership and how it can benefit your business, please visit: Kibo Composable Commerce Consultancy & Implementation — OLR

MOASC Presents Cary Presant, MD Young Investigator Award

Retrieved on: 
Tuesday, March 19, 2024
IO, Immunotherapy, Oncology, Patient, City, Research, Bacteria, Cancer, YIA, MD, Breast cancer, Multimedia, Hematology, Young, Nursing

At this symposium, Ashkan Lashkari, MD, President, presented the inaugural Cary Presant, MD Young Investigator Award to Alexis LeVee, MD, Chief Fellow, Hematology & Medical Oncology at, City of Hope National Medical Center, for her research on "Fecal microbiome and association with outcomes in patients with HER2-positive (HER2+) breast cancer (BC) receiving neoadjuvant HER2-targeted therapy and immunotherapy (IO)."

Key Points: 
  • At this symposium, Ashkan Lashkari, MD, President, presented the inaugural Cary Presant, MD Young Investigator Award to Alexis LeVee, MD, Chief Fellow, Hematology & Medical Oncology at, City of Hope National Medical Center, for her research on "Fecal microbiome and association with outcomes in patients with HER2-positive (HER2+) breast cancer (BC) receiving neoadjuvant HER2-targeted therapy and immunotherapy (IO)."
  • The Young Investigator Award (YIA) aims to support early-career researchers, typically those within a few years of completing their postgraduate training, who are conducting innovative and impactful research in clinical and translation oncology.
  • "We at MOASC are excited to provide a Young Investigator Award that honors the work of our founder, Dr. Cary Presant, who has been dedicated to the fight against cancer.
  • MOASC continually strives to ensure continued access to care, thereby assuring greater access to oncology treatments for cancer patients.

Global and China Automotive RISC-V Chip Industry Research Report 2024: Customized Chips May Become the Future Trend, and RISC-V will Challenge ARM

Retrieved on: 
Friday, March 15, 2024
ISA, Research, Certification, IO, SOC, Memory, Veyron, Qualcomm, Computing, Threshold, Electronics, RISC, Internet, IATF, ARM, IDE, Software, Architecture, IP, SiFive, Ecosystem, X86, NXP, Patent, Family, CPU, Economics, UCIe, ICT, Video game

DUBLIN, March 14, 2024 /PRNewswire/ -- The "Automotive RISC-V Chip Industry Research Report, 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 14, 2024 /PRNewswire/ -- The "Automotive RISC-V Chip Industry Research Report, 2024" report has been added to ResearchAndMarkets.com's offering.
  • In contrast, ARM and X86 are not only complicated in instruction set development, but also difficult to obtain authorization to modify instruction sets.
  • In terms of customization, it enables designers to create thousands of potential customized processors, thus speeding up the time to market.
  • In the past, automotive chips were mainly based on ARM or private architectures of some European chip companies.